Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report.

ABSTRACT:

Background

Cancer of unknown primary (CUP) is usually treated with nonselective and empirical chemotherapy; however, its prognosis is generally poor, with a median survival of less than a year. Thus, clinicians eagerly await the development of more effective treatment strategies. In recent years, advances in next-generation sequencing (NGS) have made it possible to analyze comprehensively the genome of individual cancers. NGS has identified many genomic alterations, some of which are potential molecular targets of specific agents. We report a case of CUP that was successfully treated with targeted therapy directed by the genomic data obtained from an NGS-based multiplex assay.

Case presentation

A 52-year-old Asian woman with right hip joint pain underwent fluorodeoxyglucose-

SUBMITTER: Mitani Y 

PROVIDER: S-EPMC7709432 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature